Cosentyx significantly has higher ACR response rate at week
12 starting early from week 4³

ACR20 and ACR50 responses were met and favored secukinumab-treated patients against placebo at week 12, with significant improvements observed as early as week 1 for ACR20 and week 2 for ACR50 compared with placebo3		Significantly higher responses were observed in secukinumab-treated patients for the exploratory endpoints (ACR70 response) at week 12 compared with placebo.3
Image	Image	Image
*P<0.05 versus placebo. (A) ACR20 response (NRI, odds ratio [95% CI]: 5 [2; 9], P<0.0001, relative risk: 2); (B) ACR50 response (NRI, odds ratio [95% CI]: 10 [4; 24], P<0.0001, relative risk.	*P<0.05 versus placebo. (A) ACR20 response (NRI, odds ratio [95% CI]: 5 [2; 9], P<0.0001, relative risk: 2); (B) ACR50 response (NRI, odds ratio [95% CI]: 10 [4; 24], P<0.0001, relative risk.	*ACR70 response (NRI, odds ratio [95% CI]: 23 [3; 178], P=0.0013, relative risk: 18).NRI, non responders’ imputation.

ULTIMATE: Study Design.³

Cosentyx® provides maintained improvements in signs and symptoms of PsA⁵

FUTURE 2 is a 5-year, randomized, double-blind, multicenter, placebo-controlled, parallel-group study. Briefly, patients were ≥ 18 years old with active PsA. Eligible patients were randomized (1:1:1:1) to receive subcutaneous doses of secukinumab 300 mg, 150 mg, 75 mg, or placebo at baseline, weeks 1, 2, 3, and 4, and every 4 weeks thereafter. At Week 16, placebo-treated patients were re-randomized (1:1) to receive secukinumab 300 mg or 150 mg sc from Week 16 (if they had < 20 % improvement from baseline in tender and swollen joint counts) or Week 24. Here we describe efficacy outcomes in patients naive to TNFi therapy (TNFi-naive) and those previously treated with TNFi (TNFi-exposed).⁵

Cosentyx® provides improvements in symptoms of PsA⁶

ACR20 Response at WEEK 104 

The prevalence of axial disease in patients with PsA varies with disease duration and the definition used, occurring in⁷:

Cosentyx 300 mg and 150 mg significantly improved ASAS20 vs placebo at week 12.⁷

MAXIMISE: was a phase 3b, double-blind, placebo-controlled, multi-centre 52-week trial that include 498 patients. The trial consisted of two treatment periods; a placebo-controlled period from baseline to week 12 followed by an active treatment period from week 12 to 52. Eligible patients were randomised (1:1:1) to subcutaneous (s.c.) secukinumab300 mg, 150 mg or placebo weekly for 4 weeks and every 4 weeks thereafter. The objective of the MAXIMISE trial was to specifically evaluate the efficacy and safety of secukinumab 300 mg and 150 mg in managing axial manifestations in patients with PsA with an inadequate response to non-steroidal anti inflammatory drugs (NSAIDs).⁷

Cosentyx® offers your patients structural benefits

Patients with no radiographic structural progression at week 24

*vs.Cosentyx® 150 mg without loading dose in the placebo group (73.6%).

Cosentyx® led to significant improvements in skin clearance at week 16.¹⁰

Cosentyx® provided improvements across multiple domains of PsA including signs and symptoms in patients with active disease through 3 years of treatment.

*Resolution of enthesitis are shown for patients with these symptoms at baseline (enthesitis: N=99 (150 mg)). Results are mean±SD unless otherwise stated.¹¹

92.20% Dactylitis resolution rate was observed in patients treated with cosentyx® 150 mg.⁶

Cosentyx® reduced NAPSI score at week 16 and up to week 104^12*

Non-Significant Difference 
*At Week 104, the mean percentage mNAPSI changes were -77.5%, -82.7% and -73.2% for patients originally randomized to 300 mg, 150 mg and 150 mg no load, respectively.

FUTURE 5 was a 2-year, randomised, double-blind, placebo-controlled, parallel-group Phase III study. Patients (n=996) aged ≥18 years and who met the CASPAR criteria with active PsA at screening were randomly (2:2:2:3) allocated to one of four treatment groups: secukinumab 300 mg loading dose at Weeks 0, 1, 2 and 3 followed by dosing every 4 weeks (q4w) starting at Week 4; secukinumab 150 mg loading dose at Weeks 0, 1, 2 and 3 followed by dosing q4w starting at Week 4; secukinumab 150 mg no-load received secukinumab 150 mg treatment at baseline and placebo at Weeks 1, 2 and 3 followed by secukinumab 150 mg q4w from Week 4; or matched placebo, all self-administered subcutaneous (s.c.)


Efficacy assessments through Week 104 in the nail subset included mean change from baseline in fingernail mNAPSI scores, percentage change from baseline in fingernail mNAPSI, proportion of patients achieving mNAPSI score of ≤2 (in patients with baseline mNAPSI score of >2), proportion of patients achieving ≥20/50% improvement according to American College of Rheumatology response composite index (ACR20/ACR 50) and ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90) responses and proportion of patients with resolution of dactylitis (as defined by the Leeds Dactylitis Index) and enthesitis (as defined by the Leeds Enthesitis Index).¹²

BL: baseline, csDMARD: Conventional synthetic disease-modifying antirheumatic drugs, ACR20: American Collage of Rheumatology response criteria, PsA: psoriatic arthritis , MAXIMISE: Managing AXIal manifestations in psoriatic arthritis with Secukinumab, bDMARD: Biological Disease Modifying Anti-Rheumatic Drugs, ASAS: Assessment of Spondyloarthritis international Society, S.C: Subcutaneous,  GRAPPA: Group for Research and Assessment of Psoriasis and PsA, IBD: inflammatory bowel disease, MRI: magnetic resonance imaging, PASI: Psoriasis Area and Severity Index , NAPSI: Nail Psoriasis Severity Index, mNAPSI: Modified Nail Psoriasis Severity Index .